30
Sep 2026
Streamlining CRISPR workflows, from editing to analysis
INTEGRA's automated solutions optimize CRISPR workflows, enhancing gene editing efficiency and accelerating the path to innovative therapeutic developments.
Stay Informed!
30
Sep 2026
Mouser stocking nearly 70,000 products from leading global passive component manufacturer YAGEO Group
Mouser Electronics, Inc., an authorized global distributor with the widest selection of semiconductors and electronic components, is shipping a wide array of new products and solutions from the YAGEO Group, a leading global passive component manufacturer.
30
Sep 2026
AtlasPlex™ brings custom 5-plex IHC on FFPE tissue into a single day
Atlas Antibodies has launched AtlasPlex™, a new ready-to-use multiplex immunohistochemistry kit. It lets researchers build their own 3- or 5-plex panels from more than 17,000 IHC-validated antibodies covering over 12,000 human genes.
30
Sep 2026
Atlas Antibodies marks 20 years of Human Protein Atlas–validated antibodies
Atlas Antibodies is 20 years old. The company is the original manufacturer of the antibodies used to map the human proteome in the Human Protein Atlas (HPA).
30
Sep 2026
MolBoolean™ measures free and bound proteins in the same experiment
Atlas Antibodies has launched MolBoolean™, a new in situ proximity assay. It detects free protein A, free protein B, and the A–B complex together in fixed cells and tissue.
29
Sep 2026
Exercise linked to better attention and memory after breast cancer
One in three breast cancer survivors will experience cognitive problems, which can include difficulties with attention, memory, processing speed and other aspects of thinking.
29
Sep 2026
Weekly cisplatin fails to reduce acute toxicity in advanced head and neck cancer
Physicians typically use either a higher dose of cisplatin given every three weeks or a lower dose given weekly in combination with radiation to treat locally advanced head and neck cancer.
29
Sep 2026
Petrelintide produces double-digit weight loss with fewer side effects
New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Diabetes & Endocrinology shows that weekly injections with the new amylin-based obesity drug petrelintide can enable those treated to lose more than 10% of their body weight – generally lower than existing incretin-based (GLP-1 RA) drugs, but also with far fewer side effects.
29
Sep 2026
Flexible work and fair pay could help create healthier jobs, researchers say
Fewer late-night emails and greater flexibility at work could help keep millions of people healthier, according to experts at the University of East Anglia.
29
Sep 2026
Researchers found a curious mitochondrial pattern in people who moved more
Researchers found that greater self-reported activity, walking, and accelerometer-measured light activity were associated with higher mitochondrial DNA copy number in 256 healthy middle-aged adults. The cross-sectional findings cannot establish causation, and the very low amount of vigorous activity means they do not show that light movement is more beneficial than higher-intensity exercise.
